EFAI NEUROSUITE CTA LVO ASSESSMENT SYSTEM (LVO-CTA-100)
Ever Fortune.Ai, Co., Ltd. · Decision date Oct 30, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 10/30/2026 for K263109, the EFAI NEUROSUITE CTA LVO ASSESSMENT SYSTEM (LVO-CTA-100), submitted by Ever Fortune.Ai, Co., Ltd. of Taichung City, Taiwan. The submission was received 09/04/2026 and reviewed under regulation 892.2080 in the Radiology specialty, with product code QAS and the device classification name Radiological Computer-Assisted Triage And Notification Software. This is a 510(k) clearance, not a PMA approval.
The record describes a Traditional 510(k) that was not reviewed by a third party, was not a combination product, and had no authorized Predetermined Change Control Plan. The listed summary is the only linked document; the source does not include the predicate device, the cleared indications for use, or any performance data, so the specific intended use and the basis for substantial equivalence remain unknown from this record.
No clinical, efficacy or patient-selection conclusions are drawn here; those details would reside in the FDA summary document, which was not provided in the source data.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Oct 30, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K263109
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Ever Fortune.Ai, Co., Ltd.
- Product code
- QAS
- Decision code
- SESE
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Radiological Computer-Assisted Triage And Notification Software.
- Applicant
- Ever Fortune.Ai, Co., Ltd.
- Product code
- QAS
- FDA device class
- 2
FDA decision timeline
K263109 received
Application receipt date recorded by FDA.
K263109 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QAS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Rapid ICH (v4.0)K262301 | Ischemaview, Inc. | 510(k) clearance | Oct 9, 2026 | FDA |
a2z-Abdo-TriageK260906 | A2z Radiology Ai, Inc. | 510(k) clearance | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ever Fortune.Ai, Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Taichung City
Sources and methodology
- Original FDA record: K263109
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
